Novo Seeds to invest more in medtech
Medtech investments will make up a bigger part of Novo Seeds’ portfolio in coming years, says managing partner Søren Carlsen, while Novo Ventures has had a bad experience with a US investment in the field.
BY STEFAN SINGH KAILAY
In recent years, the venture market has seen a shift from drug development to medtech when it comes to early-stage investment and that change is also happening in Novo Seeds, says Søren Carlsen, managing partner in Novo Seeds and Novo Ventures.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo Ventures follows dual investment approach
For abonnenter
Novo Seeds in biggest ever licensing deal
For abonnenter
Gilead Sciences buys Danish biotech company
For abonnenter
